Vistagen gets FDA feedback on fasedienol Phase 3 path, reports Q2 FY2027 results
FDA offered feedback on a planned Phase 3 study of fasedienol in social anxiety disorder as Vistagen posted a $10.7 million net loss and $20 million in cash as of September 30, 2026.
Vistagen reported on November 13, 2026 that it held a Type C meeting with the FDA regarding a potential Phase 3 study of fasedienol in adults with social anxiety disorder, with the agency offering feedback that touched on using the Liebowitz Social Anxiety Scale as the primary endpoint and on interim assessments meant to show whether fasedienol's acute effects could translate into longer-term functional improvement over time.1 The agency also acknowledged fasedienol's reported safety profile and its potential to help a broad population of SAD patients.1 Based on this input, Vistagen said it now plans to focus future Phase 3 work on overall treatment of SAD, not just acute treatment, across the general SAD population.1
The company also disclosed preliminary open-label extension data from its PALISADE-4 Phase 3 trial of fasedienol for acute SAD treatment. It said the OLE results showed improvement in social anxiety over a four-month period, based on both clinician-rated and patient-reported versions of the LSAS.1 Vistagen said earlier Phase 2 placebo-controlled data combined with PALISADE program OLE results support the idea that as-needed fasedienol dosing, up to six times daily, can provide benefit in anxiety-provoking situations over time.1
In corporate updates, Vistagen named Douglas J. Williamson, MD to its board, citing his background in neuroscience drug development and commercialization at companies including Acadia Pharmaceuticals, Eli Lilly, Lundbeck, Avadel Pharmaceuticals, and QurAlis.1 The company also said it has implemented cost-management steps meant to focus spending on priority clinical programs and extend its operating runway.1
Financially, R&D expense fell to $6.6 million from $15.9 million a year earlier, and net loss narrowed to $10.7 million from $19.4 million, driven largely by lower clinical costs after completion of OLE phases in the PALISADE-3 and PALISADE-4 studies and reduced headcount.1 Cash, equivalents, and marketable securities stood at $20.0 million as of September 30, 2026, and the company said this is expected to fund operations into 2027 but not beyond one year from now.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.